文献速递临床生化临床免疫

三种方法测定脂蛋白相关磷脂酶A2:ELISA与活性检测不一致的探索

Measurement of Lipoprotein-Associated Phospholipase A2 by Use of 3 Different Methods: Exploration of Discordance between ELISA and Activity Assays.
PubMed 文献 · Clin Chem · 2018-01-10

研究开发了两种基于LC-MS/MS的血清Lp-PLA2活性与浓度检测方法,并与商业比色活性和免疫浓度法比较。SISCAPA质谱法测得的浓度显著高于免疫法且与活性一致性更好;去垢剂可释放脂蛋白复合物中的Lp-PLA2,大幅提高免疫法检测量并改善与活性的一致性。

要点

  • 免疫法测Lp-PLA2浓度受脂蛋白结合抑制,与活性检测结果不一致。
  • LC-MS/MS定量浓度与活性一致性优于传统免疫法。
  • 去垢剂释放Lp-PLA2可提高免疫法检测量并改善与活性一致性。

核心结论

  • LC-MS/MS定量Lp-PLA2浓度与活性有助于解决免疫法与活性检测间的不一致。
  • 免疫法定量Lp-PLA2受脂蛋白相互作用强烈抑制。

研究设计与样本

  • 开发2种LC-MS/MS方法:多重反应监测检测产物定量活性,SISCAPA免疫亲和定量浓度。
  • 与商业比色活性法和免疫浓度法比较相关性。
  • 用免疫沉淀和Western blot评估Lp-PLA2与脂蛋白关联及去垢剂释放效果。

主要发现

  • SISCAPA质谱法测得的血清Lp-PLA2浓度显著高于免疫法通常测得的浓度。
  • 质谱法浓度与Lp-PLA2活性一致性更好。
  • 去垢剂使免疫法检测到的Lp-PLA2蛋白量大幅增加,并改善与活性测量的一致性。

临床怎么用

  • 免疫法测Lp-PLA2浓度可能受脂蛋白结合抑制,解读风险分类时应考虑方法学差异。
  • LC-MS/MS(SISCAPA测浓度、直接产物检测测活性)可提供更一致的Lp-PLA2定量结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme associated with inflammation, is used as a biomarker for cardiovascular disease risk. Both the concentration and activity of Lp-PLA2 have been shown to be clinically relevant. However, there is a discordance between the serum concentration of Lp-PLA2 measured by the standard ELISA-based immunoassays and the activity of this enzyme, leading to substantial discordance in risk categorization depending on assay format. METHODS: We developed 2 LC-MS/MS-based assays to quantify serum Lp-PLA2 activity (multiple reaction monitoring detection of product) and concentration [stable isotope standards and capture by antipeptide antibody (SISCAPA) immunoaffinity], and we investigated their correlation to commercially offered colorimetric activity and immunometric concentrations assays. Associations between Lp-PLA2 and lipoproteins and the effect of selected detergents in liberating Lp-PLA2 were evaluated by use of immunoprecipitation and Western blot analyses. RESULTS: Serum Lp-PLA2 concentrations measured by quantitative SISCAPA-mass spectrometry were substantially higher than concentrations typically measured by immunoassay and showed an improved agreement with Lp-PLA2 activity. With detergents, liberation of Lp-PLA2 from lipoprotein complexes dramatically increased the amount of protein detected by immunoassay and improved the agreement with activity measurements. CONCLUSIONS: Quantitative analysis of Lp-PLA2 concentration and activity by LC-MS/MS assays provided key insight into resolving the well-documented discordance between Lp-PLA2 concentration (determined by immunoassay) and activity. Quantitative detection of Lp-PLA2 by immunoassay appears to be strongly inhibited by interaction of Lp-PLA2 with lipoprotein. Together, the results illustrate the advantages of quantitative LC-MS/MS for measurement of Lp-PLA2 concentration (by SISCAPA) and activity (by direct product detection).

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Topbas C, Swick A, Razavi M, et al. Measurement of Lipoprotein-Associated Phospholipase A2 by Use of 3 Different Methods: Exploration of Discordance between ELISA and Activity Assays. Clin Chem. 2018. PMID: 29321128. doi:10.1373/clinchem.2017.279752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。